Macrodantin (Oral)

Quick links

Choose a section

Quick links to important sections

Advertisements

Macrodantin (Oral)

Selected form

Advertisements
Advertisements

Overview of Macrodantin (Oral)

What is Macrodantin (Oral)?

Macrodantin is an antibacterial medication specifically used to treat and prevent urinary tract infections (UTIs). It contains the active ingredient nitrofurantoin, which belongs to a class of medications known as nitrofuran antibiotics.

How it Works

Unlike many broad-spectrum antibiotics that affect bacteria throughout the entire body, Macrodantin is designed to concentrate in the urine. This makes it highly effective for targeting bacteria located within the urinary tract, including the bladder and kidneys.

Once the medication enters the bacterial cells, it is converted into reactive intermediates. These intermediates attack multiple targets within the bacteria, including:

  • DNA and RNA synthesis: Preventing the bacteria from replicating.
  • Protein synthesis: Stopping the production of essential bacterial proteins.
  • Cell wall synthesis: Weakening the structural integrity of the bacterial cell.
  • Metabolic processes: Disrupting the energy production of the cell.

Because the medication attacks several different bacterial processes simultaneously, it is generally more difficult for bacteria to develop resistance to Macrodantin compared to some other types of antibiotics.

Common Uses

Macrodantin is typically prescribed for the treatment of acute, uncomplicated urinary tract infections caused by specific strains of susceptible bacteria, such as Escherichia coli, Enterococci, Staphylococcus aureus, and certain strains of Klebsiella and Enterobacter species.

In some cases, it may also be used as a preventive measure (prophylaxis) for individuals who experience recurrent urinary tract infections. It is important to note that Macrodantin is only effective against bacterial infections and will not work for viral infections, such as the common cold or flu.

Advertisements

What side effects are possible with Macrodantin (Oral)?

Possible Side Effects and Safety Information

The safety profile of Macrodantin (nitrofurantoin) is officially documented by regulatory authorities, classifying adverse reactions by frequency and the body system affected. These classifications differentiate between common events and rare, clinically significant reactions.


Adverse Reaction Classification

Classification Examples of Reactions
Common Nausea, vomiting, anorexia, and flatulence. These are often dose-related and may diminish over time.
Uncommon Diarrhea and abdominal pain.
System-Organ Classes Effects documented across Gastrointestinal, Nervous System, Respiratory, Hepatobiliary, and Blood and Lymphatic System Disorders.

Serious and Time-Related Safety Considerations

The official labeling notes the possibility of rare but serious adverse reactions with the potential for irreversible consequences. These include Peripheral Neuropathy, and potentially fatal Pulmonary Reactions (such as pulmonary fibrosis) and Hepatic Reactions (including chronic active hepatitis or hepatic necrosis).

Time- or Duration-Related Patterns:

  • Acute Pulmonary Reactions typically occur within the first week of treatment.
  • Chronic Pulmonary Reactions are generally associated with continuous therapy for six months or longer.

Population-Specific Restrictions:

Macrodantin is contraindicated in specific patient groups, as defined in regulatory documents:

  • Patients with severe Renal Impairment (eGFR <45 mL/min/1.73m^2 is often cited) due to risk of toxicity.
  • Individuals with a known G6PD deficiency.
  • Infants under one month of age and pregnant patients at term (labor and delivery) due to the risk of hemolytic anemia.

An expected, non-serious effect is a rust-yellow to brown discoloration of the urine.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The officially documented overdose profile for Macrodantin (nitrofurantoin) is characterized by acute gastrointestinal manifestations. The clinical signs specifically noted in regulatory documentation for overdosage include vomiting, gastric irritation, and nausea. Severe outcomes are not explicitly listed as acute results of overdosage in these sections.

In any instance of known or suspected overdosage, urgent medical attention is required. Individuals must seek emergency medical attention or contact a poison control center immediately, as directed by official response statements.

Crucially, no specific antidote is known for nitrofurantoin overdosage. Therefore, the required management is strictly supportive and symptomatic. Regulator-mandated clinical procedures include maintaining a high fluid intake with the aim of promoting the urinary excretion of the drug. Other documented measures involve consideration of induction of emesis (vomiting) and gastric lavage. The drug is noted to be dialyzable and, following exposure, the official prescribing information recommends monitoring of full blood count, liver function, and pulmonary function tests to assess potential systemic effects. No population-specific overdose considerations are detailed in the regulatory overdosage sections.

Advertisements

Therapeutic Uses of Macrodantin (Oral)

What Macrodantin (Oral) Treats: Main Uses and Benefits

Support for Symptomatic Relief

The medication is commonly used in the management of conditions involving the urinary tract, which may be characterized by specific symptom patterns, including physical discomfort, heightened physiological activity, and noticeable physiological strain. It is applied across therapeutic domains where additional symptomatic support is needed, helping to address symptom clusters that may appear suddenly or fluctuate. This provides support that helps ease the overall symptom burden. The treatment is relevant in conditions characterized by periods of heightened symptoms or episodic manifestations.

Assistance During Acute Episodes and Functional Strain

The treatment is commonly used in contexts involving conditions that present with systemic or localized discomfort. The medication is often used in clinical settings that involve acute or disruptive symptom patterns, assisting with managing these symptom groups. The treatment may assist with maintaining functional stability when symptoms interfere with routine activities. This approach is relevant in areas where short-term symptom management is appropriate and contributes to easing the overall symptom load when symptoms escalate temporarily.

Quick Fact: Supports Management of Physical Discomfort

Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Macrodantin (Oral) — official regulatory information

Populations for Whom Use is Prohibited (Contraindicated)

Macrodantin (nitrofurantoin) is contraindicated (must not be used) for several specific patient groups due to increased risks of toxicity or serious complications. Use is strictly prohibited for:

  • Patients with known hypersensitivity (allergy) to nitrofurantoin.
  • Patients with significant impairment of renal function, including anuria, oliguria, or a creatinine clearance of less than 60 mL per minute, because impaired excretion increases the risk of toxicity.
  • Patients with a previous history of cholestatic jaundice or hepatic dysfunction associated with nitrofurantoin.
  • Pregnant patients at term (generally 38 to 42 weeks' gestation), during labor and delivery, or when the onset of labor is imminent, due to the risk of hemolytic anemia in the newborn.
  • Neonates (infants) under one month of age for the same reason.

Eligibility-Related Restrictions and Special Considerations

  • Lactation: Use is generally not recommended when breastfeeding an infant under one month old or an infant with a known Glucose-6-phosphate dehydrogenase (G6PD) deficiency, as this may lead to hemolytic anemia in the infant.
  • Conditions Requiring Caution: Use requires caution or special monitoring in patients with conditions that may enhance the risk of peripheral neuropathy, such as renal impairment, anemia, diabetes mellitus, electrolyte imbalance, or vitamin B deficiency. Caution is also advised for patients with pulmonary disease or hepatic dysfunction.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Macrodantin (nitrofurantoin macrocrystals) has documented interactions with specific medication categories and products that can impact its effectiveness or increase the risk of systemic effects.

Interacting Product Category Specific Examples Documented Mechanism and Result
Antacids Magnesium trisilicate Reduces the rate and extent of Macrodantin absorption, likely through adsorption onto the antacid surface, which may reduce antibiotic efficacy.
Uricosuric Drugs Probenecid, Sulfinpyrazone These agents can inhibit renal tubular secretion of Macrodantin. This effect increases Macrodantin levels in the blood, which may raise the risk of systemic toxicity, while simultaneously lowering its concentration in the urine, potentially lessening its efficacy against urinary tract infections.
Quinolone Antimicrobials Specific antibiotics (e.g., Ciprofloxacin) Antagonism has been demonstrated in laboratory (in vitro) studies. The clinical significance of this finding in patients is not fully established.

It is essential for patients to inform their healthcare providers about all medicines, supplements, and antacids they are taking to manage these potential drug interactions.

Advertisements

Mechanism of Action

How Macrodantin (Oral) Works


Enzyme-Dependent Cellular Assault

This core mechanistic domain explains how Macrodantin (Nitrofurantoin) functions as a prodrug that is specifically activated by bacterial nitroreductase enzymes. Once reduced, it generates toxic reactive intermediates that simultaneously attack multiple vital cellular structures, including DNA, ribosomes, and metabolic enzymes. This comprehensive, multi-target cellular destruction results in the physical destruction and population reduction of susceptible bacteria.


Functional Confinement to the Urinary Tract

This domain covers the critical physiological consequence of the drug's action being restricted to the urinary system. The drug is rapidly filtered from the bloodstream and achieves exceptionally high concentrations in the urine, ensuring the multi-target mechanism operates primarily at the site of high drug concentration. This localized delivery establishes a high-concentration cytotoxic environment within the urinary tract. The rapid renal excretion results in low systemic concentrations.


Mechanism Limitations: Intrinsic Constraints

This domain clarifies the boundaries of the mechanism's function. The drug's action is fundamentally limited by two factors: the mandatory need for the bacterial activating enzyme (leading to intrinsic resistance in some species), and the physiological constraint of low tissue penetration. This lack of systemic distribution means the mechanism cannot achieve the required cytotoxic concentration in deep tissues (e.g., the kidney parenchyma), rendering the mechanism ineffective outside of the localized urinary environment.

Advertisements

Dosage and Administration Information

How to Use Macrodantin (Oral)

Macrodantin (nitrofurantoin macrocrystals) is administered via the oral route as a capsule or oral suspension.

Administration Scope

Instruction Entity Administration Details
Route of Administration Oral (capsule or suspension).
Timing in Relation to Meals Must be taken with food or milk to enhance absorption and improve tolerance.
Preparation Requirements The oral suspension must be shaken vigorously before each dose is measured.

Standard Dosage and Schedule

The dosage regimen is determined by the required duration of use and the type of treatment prescribed by a healthcare professional.

Regimen Type Standard Adult Dosing (Macrocrystals) Frequency and Duration
Acute Treatment 50 mg to 100 mg Four times daily (q.i.d.) for 7 days.
Long-Term Suppression 50 mg to 100 mg Once daily (q.d.), typically at bedtime, for up to 12 months.

Population-Specific and Procedural Rules

Age-Group Administration Rules:

  • Pediatric Patients: For infants ge 3 months, treatment dosing is calculated by weight at 5 to 7 mg/kg/day in four divided doses. Suppressive dosing is 1 mg/kg/day once daily.
  • Older Adults: Standard adult dosing applies, contingent upon having no significant impairment of renal function.

Special Procedural Conditions:

  • The macrocrystal capsules may be opened, and the contents mixed with food or liquid to aid administration for patients with difficulty swallowing.
  • If a dose is missed, it is advised to skip the missed dose and take the next dose at the regular scheduled time. Do not take two doses to compensate for the missed one.

This structured application of dosing, frequency, and administration conditions is designed to ensure the consistent use of the medication.

Advertisements

Recent Clinical Evidence

Recent Clinical Evidence Summary

Macrodantin (nitrofurantoin) is an antibiotic primarily studied for the treatment and prevention of uncomplicated lower urinary tract infections (UTIs), such as cystitis, in adults. Recent clinical guidelines often recommend nitrofurantoin as a first-line treatment option for acute, uncomplicated UTIs, largely due to its sustained activity against common uropathogens like Escherichia coli.

Efficacy and Comparisons

  • Uncomplicated UTI Treatment: Studies have consistently found nitrofurantoin to be clinically equivalent to several other common comparator antibiotics used for acute uncomplicated cystitis. Its effectiveness is attributed to achieving high concentrations within the urine.
  • Resistance: Research indicates that the bacterial resistance rates to nitrofurantoin remain relatively low in community-acquired E. coli strains compared to some other older and newer antibiotic classes.
  • Prophylaxis: Nitrofurantoin is also investigated for long-term, low-dose prophylaxis (prevention) of recurrent UTIs. Clinical trials have assessed the reduction in recurrence rates when compared to placebo or no treatment, as well as against other prophylactic agents.

Safety and Tolerability

Safety protocols in clinical trials track adverse events over both short and long treatment courses. Common adverse events reported in studies include gastrointestinal upset, nausea, and headache.

Long-term use (typically defined as continuous daily dosing for six months or longer) is associated with the potential for serious, though rare, adverse reactions affecting the lungs (pulmonary toxicity) and liver (hepatotoxicity). For this reason, guidelines emphasize monitoring and careful risk assessment for individuals prescribed long-term therapy.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Macrodantin (Oral) (FAQ)


Q: Is Macrodantin an antibiotic, and how is it different from other antibiotics?

A: Macrodantin is an antibacterial agent with the active ingredient nitrofurantoin. According to official product information, it belongs to the unique nitrofuran chemical class. Its mode of action differs from many common antibiotics because it is activated by bacterial enzymes and interferes with several bacterial enzyme systems simultaneously.


Q: Can Macrodantin cause severe diarrhea or a C. difficile infection?

A: Yes, regulatory documents indicate that severe diarrhea, known as Clostridium difficile-associated diarrhea (CDAD), has been reported with the use of nearly all antibacterial agents, including nitrofurantoin. CDAD can range in severity from mild diarrhea to colitis. Patients experiencing severe diarrhea during or after treatment should seek guidance from a healthcare professional.


Q: Can Macrodantin interact with diabetes medications or affect urine sugar tests?

A: Official information cautions that pre-existing conditions like diabetes mellitus may enhance the risk of a serious nerve condition called peripheral neuropathy while using this medicine. Furthermore, nitrofurantoin can cause false-positive results when testing for sugar in the urine using certain old methods, such as Benedict’s and Fehling’s solutions.


Q: Can Macrodantin cause dizziness or drowsiness, and will it affect my ability to drive?

A: Yes, dizziness and drowsiness have been reported as possible side effects, though their frequency is not fully known. Due to the potential for these effects, official labeling indicates that patients should use caution when performing tasks that require full mental alertness, such as driving or operating heavy machinery.


Q: Does Macrodantin cause temporary hair loss?

A: Temporary hair loss, or alopecia, has been reported rarely with nitrofurantoin formulations according to post-marketing data. Any patient concerned about this side effect should consult with a healthcare professional.


Q: Does Macrodantin interact with any common herbal supplements?

A: Official drug information advises patients to inform their healthcare provider about all medicines, supplements, and herbal remedies they are taking. It is important for patients to discuss the use of all supplements with their healthcare provider, as herbal remedies are not always tested for interactions with prescription drugs.


Q: Can Macrodantin interfere with certain lab tests, besides urine glucose tests?

A: Yes, in addition to the known interference with certain urine sugar tests (using specific chemical solutions), Macrodantin has been reported to affect certain serum lab values. For example, official reports indicate that it can cause an increase in serum phosphate levels.


Q: Does taking Macrodantin make me more susceptible to getting a yeast infection (thrush)?

A: Yes, official labeling notes that taking Macrodantin, like other antibacterials, may result in superinfections. These are new infections caused by resistant organisms, and they commonly include yeast infections caused by Candida species (thrush).


Q: Can Macrodantin affect the production or health of sperm cells?

A: Regulatory documents indicate that high doses of Macrodantin may, in some instances, produce a temporary halt in sperm production (spermatogenic arrest) in healthy males. This effect is associated with a decrease in sperm count.


Q: Are there specific vitamins or minerals that should be avoided while on Macrodantin?

A: Official label information notes that antacids containing magnesium trisilicate may reduce the absorption and effectiveness of Macrodantin. Additionally, a Vitamin B deficiency may enhance the risk of the serious side effect known as peripheral neuropathy.


Q: Is Macrodantin effective against infections in other parts of the body, or just the urinary tract?

A: Official FDA labeling clearly indicates that Macrodantin is used only for the treatment of specific urinary tract infections (UTIs). It is not intended to treat systemic infections or those outside of the urinary system, due to its low tissue penetration.


Q: What are the risks of using Macrodantin for long-term UTI prevention?

A: Long-term suppressive use, typically for six months or longer, carries an increased potential for rare but serious adverse reactions. These include chronic or subacute problems affecting the lungs (pulmonary reactions) and the liver (hepatic reactions). For these reasons, the use of long-term therapy requires careful risk assessment.


Q: Is it better to take Macrodantin in the morning or at night?

A: The administration timing depends on the specific regimen prescribed. For acute treatment, the drug is typically taken four times daily. However, for long-term prevention (suppression), the regulatory guidance often recommends taking the single daily dose at bedtime.


Q: Can Macrodantin cause an increase in gas or flatulence?

A: Yes, the official label lists flatulence (gas) as one of the common gastrointestinal adverse reactions reported by patients taking Macrodantin. These common side effects are sometimes dose-related.


Q: Does Macrodantin have a risk of causing severe skin reactions like Stevens-Johnson syndrome?

A: Yes, serious skin reactions, including Stevens-Johnson syndrome (SJS), have been reported rarely with nitrofurantoin formulations according to official labeling for hypersensitivity reactions.


Q: How is Macrodantin eliminated from the body?

A: Official pharmacology data states that Macrodantin is readily absorbed after being taken and is then rapidly excreted from the body. This occurs primarily through the kidneys into the urine via both glomerular filtration and tubular secretion.


Q: Can Macrodantin cause vision changes or eye pain?

A: Rare neurological adverse reactions have been reported with the use of nitrofurantoin. These include vision changes linked to benign intracranial hypertension (increased pressure around the brain) and a condition called optic neuritis.


Q: How does Macrodantin compare to Macrobid, since they both contain nitrofurantoin?

A: Both are brand names for nitrofurantoin, but they use different formulations. Macrodantin contains only nitrofurantoin macrocrystals. Macrobid contains a combination of nitrofurantoin monohydrate and macrocrystals, which affects how the drug is absorbed and released.


Q: Why does Macrodantin require a more frequent dosing schedule than Macrobid?

A: The difference is due to the formulation. The mix of monohydrate and macrocrystals in Macrobid creates a unique, slow-release system that allows the drug to be taken twice daily. Macrodantin's macrocrystals formulation has a different absorption profile, which requires a more frequent dosing schedule to maintain adequate levels in the urine.


Advertisements

How should Macrodantin (Oral) be stored and disposed of?

Official Storage and Disposal Profile for Macrodantin (Nitrofurantoin Macrocrystals) Oral Formulations

Macrodantin must be stored according to specific regulatory requirements to maintain product quality and safety, strictly based on official government labeling.

Category Requirement Summary
Temperature Control Store at controlled room temperature (e.g., 20 C to 25 C); keep away from excess heat and freezing (suspension).
Environmental Protection Keep in the original container, tightly closed, protected from moisture and direct light.
Stability / Handling The oral suspension expires 30 days after opening. Shake the liquid well before use.
Child Safety Keep out of the reach and sight of children at all times.
Disposal Dispose of unused or expired medicine according to local requirements; do not keep outdated medication.

This medication must be protected from environmental degradation and kept securely stored away from children until it is properly discarded following official local disposal guidance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Macrodantin (Oral) found in:

A-Z Index: